INTRODUCTION
============

The classic role of vitamin D involves regulation of calcium and bone metabolism. In recent years, other roles of vitamin D have been elucidated by the nonskeletal effects of this vitamin associated with chronic disease.[@b1-gnl-10-818] Vitamin D deficiency is highly prevalent in patients with chronic liver disease (CLD) regardless of the etiology[@b2-gnl-10-818] and is known to be associated with liver dysfunction and mortality.[@b3-gnl-10-818] Vitamin D plays an important role in the progression of fibrosis and the inflammatory response.[@b4-gnl-10-818] Previous experimental studies indicated that vitamin D can reduce collagen expression and profibrotic factors as well as having immunomodulatory effects on immune cells, including T lymphocytes.[@b5-gnl-10-818] A recent study revealed an antifibrotic effects of vitamin D on human primary transforming growth factor-β-stimulated hepatic stellate cells.[@b6-gnl-10-818]

Liver fibrosis is the main determinant of the prognosis of CLD.[@b7-gnl-10-818] Therefore, accurate assessment of the degree of fibrosis is an important factor for determining the prognosis and establishing a therapeutic strategy in patients with CLD. Although liver biopsy is the gold standard for evaluation of liver fibrosis, it is invasive and is associated with rare but potentially life-threatening complications. In addition, the accuracy of liver biopsy is questionable because of sampling error and poor interobserver reproducibility.[@b8-gnl-10-818]

Transient elastography (TE) is a promising noninvasive method of measuring liver fibrosis. The main advantage of TE is that reproducible information can be obtained rapidly from a much larger portion of the liver.[@b9-gnl-10-818] TE shows good performance in evaluating the longitudinal response to antiviral treatment in patients with chronic hepatitis C virus (HCV) and chronic hepatitis B virus (HBV) infection,[@b10-gnl-10-818] and it has been shown to be clinically useful in patients with alcoholic liver disease.[@b11-gnl-10-818]

The relationship between liver fibrosis and the vitamin D level in patients with chronic HCV infection has been widely observed in many studies.[@b12-gnl-10-818]--[@b15-gnl-10-818] However, this relationship in patients with liver disease of etiologies other than chronic HCV infection is less clear. Grünhage *et al*.[@b16-gnl-10-818] evaluated liver disease of various etiologies, and Efe *et al*.[@b17-gnl-10-818] evaluated autoimmune liver disease, with regard to the inverse relationship between serum vitamin D level and liver fibrosis. Although the study of Grünhage *et al*.[@b16-gnl-10-818] included various etiologies, most patients had chronic HCV infection (60.8%), and all patients were of Caucasian ethnicity.

In this study, we evaluated the correlation between the 25-hydroxyvitamin D (25(OH)D) level and liver fibrosis using TE in Korean patients with CLD.

MATERIALS AND METHODS
=====================

1. Patients
-----------

We performed a retrospective analysis of prospectively collected data from all patients with CLD who underwent TE and measurement of serum 25(OH)D level at intervals of \<3 months at the outpatient clinic of Soonchunhyang University Hospital, Bucheon, Korea, from January 2013 to June 2014.

A total of 260 patients were enrolled in this study. Patients were excluded from the present analysis if they had decompensated liver cirrhosis, a malignant disease (including hepatocellular carcinoma) or medications known to affect vitamin D metabolism, including vitamin or mineral supplements (calcium, vitamin D, or hormonal therapy), or pregnancy. Cirrhosis was diagnosed on the basis of clinical and radiological features or liver histology.[@b18-gnl-10-818] Decompensated liver cirrhosis was considered present when ascites, hepatic encephalopathy, hepatorenal syndrome, and/or esophageal variceal bleeding, were/was evident. After exclusion of these patients, a total of 207 patients were included in the analysis.

In addition to epidemiological data, the following biological parameters of all patients were evaluated at the time of liver stiffness (LS) measurement: serum aspartate aminotransferase (AST) level, serum alanine aminotransferase (ALT) level, creatinine level, platelet count, albumin level, total bilirubin level, γ-glutamyl transpeptidase (GGT) level, basal insulin level, and fasting glucose level. The AST/platelet ratio index (APRI) was calculated as follows: \[(AST/upper limit of normal with normal considered as 40 IU/L/platelet count×10^9^/L)×100\].[@b19-gnl-10-818] The fibrosis-4 index (FIB-4) was calculated as follows: (age×AST)/(platelet count×root ALT).[@b20-gnl-10-818] The basal insulin and fasting glucose levels were calculated with the homeostasis model for assessment-insulin resistance (HOMA-IR) as follows: fasting blood glucose (mg/dL)×fasting insulin/405. The cause of CLD was determined using standard diagnostic criteria. HCV or HBV infection was diagnosed by serological detection of HCV antibodies and HBV surface antigen, respectively.[@b21-gnl-10-818],[@b22-gnl-10-818] Alcoholic liver disease was defined as a disease associated with consumption of ≥40 g alcohol daily for ≥5 years.[@b23-gnl-10-818] Other diseases were diagnosed using currently recognized criteria.[@b24-gnl-10-818],[@b25-gnl-10-818]

This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of Soonchunhyang University Hospital.

2. Assessment of serum 25(OH)D level
------------------------------------

The serum 25(OH)D level was analyzed by isotope-dilution liquid chromatography-tandem mass spectrometry. The vitamin D status was defined according to the following 25(OH)D levels: deficiency, \<10 ng/mL; insufficiency, \<20 ng/mL; and sufficiency, ≥20 ng/mL.[@b26-gnl-10-818]

3. Liver stiffness measurement
------------------------------

LS values were measured by a single experienced technician (\>5,000 examinations) using a TE device (FibroScan^®^; Echosens, Paris, France) according to previously described methods.[@b27-gnl-10-818] The results are expressed as kilopascals (kPa). The interquartile range (IQR) was defined as the index of intrinsic variability of LS values corresponding to the interval of LS results containing 50% of the valid measurements between the 25th and 75th percentiles. In the present study, LS values with ≥10 validated measurements and an IQR-to-median-value ratio (IQR/M) of \<0.3 were considered reliable. The fibrosis stage was defined according to the LS score as measured by TE: no or minimal fibrosis (Equivalent to Metavir F0--F1), \<7.1 kPa; moderate fibrosis (F2), 7.1 to 9.4 kPa; severe fibrosis (≥F3), ≥9.5 kPa.[@b9-gnl-10-818] Moreover, advanced liver fibrosis (≥F3) was defined as a fibrosis score of ≥9.5 kPa.

4. Statistical analyses
-----------------------

Statistical analysis was performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Normally distributed continuous variables are expressed as the means±standard deviation, skew-distributed continuous variables are expressed as the median (IQR), and categorical variables are expressed as the number and percentage. Fisher exact test or the chi-squared test was used to compare categorical variables. Differences between continuous variables were examined with Student t-test or the Mann-Whitney U test, as appropriate. Correlations were tested with Spearman correlation coefficient. Comparison of LS among different vitamin D statuses was performed using the Kruskal--Wallis test. Univariate and multivariate logistic regression analyses with backward elimination were used to investigate factors associated with advanced liver fibrosis (TE ≥9.5 kPa). We also assessed the association between vitamin D concentration and seasonal timing of sampling to evaluate the general influence of sun exposure on vitamin D level (April to September vs October to March). In all analyses, p-value \<0.05 was taken to indicate statistical significance.

RESULTS
=======

1. Patient characteristics
--------------------------

The 25(OH)D level and LS value determined by TE were measured in 260 patients with CLD. Fifty-three patients were excluded because they met the exclusion criteria; 27 patients had decompensated liver cirrhosis, 19 had malignant disease, five were taking a medication that affected vitamin D metabolism, and two were pregnant. Of the 27 patients excluded due to decompensated liver cirrhosis, all exhibited ascites; one had hepatic encephalopathy, six had no evidence of esophageal varices, and eight had endoscopic varices of grade I, eight varices of grade II, and five varices of grade III. Finally, 207 patients were included in the study ([Fig. 1](#f1-gnl-10-818){ref-type="fig"}).

The patients' characteristics are summarized in [Table 1](#t1-gnl-10-818){ref-type="table"}. The mean age of the patients was 48 years old, 151 were men, and 56 were women. Twenty-eight patients had hypertension as a comorbidity, and 36 had diabetes mellitus (DM). About 60% of patients had chronic HBV or HCV infection. Other causes included nonalcoholic fatty liver disease (NAFLD) (n=25), alcoholic liver disease (n=41), and other conditions (n=16; autoimmune disease in 4, primary biliary cirrhosis in 3, toxicity in 3, and cryptogenic liver disease in 6). All patients had well-preserved liver function. The mean AST level was 42.2 IU/L, ALT level was 40.8 IU/L, serum creatinine level was 1.0 mg/dL, platelet count was 203.5×10^9^/L, serum albumin level was 4.2 g/dL, and total bilirubin level was 1.02 mg/dL. The median serum 25(OH) D level was 12.7 ng/mL (IQR, 9.0 to 18.6 ng/mL). A total of 94 (45%) patients had vitamin D insufficiency defined as a serum 25(OH)D level of 10 to 20 ng/mL, and 72 (34%) had vitamin D deficiency defined as a serum 25(OH)D level \<10 ng/mL. The median LS determined by TE was 6.8 kPa (IQR, 5.0 to 11.5 kPa). In total, 107 (51.7%) patients had minimal fibrosis (\<7.1 kPa), 25 had moderate fibrosis (≥7.1 to \<9.5 kPa), and 75 had severe fibrosis (≥9.5 kPa). The mean Child-Pugh score was 5.27. The vitamin D level and LS showed a significant inverse correlation (r=−0.190, p=0.006).

2. Comparison of patients by vitamin D status (\<10 ng/mL vs ≥10 ng/mL)
-----------------------------------------------------------------------

[Fig. 2](#f2-gnl-10-818){ref-type="fig"} shows the distribution of LS values according to the vitamin D status. There were significant differences among the deficiency, insufficiency, and sufficiency groups (p=0.001). In the vitamin D deficiency group (\<10 ng/mL), the LS value was significantly different from those in the sufficiency (≥20 ng/mL) and insufficiency groups (\<20 ng/mL). However, we found no differences between the sufficiency and insufficiency groups. Patient characteristics according to the 25(OH)D levels (\<10 ng/mL vs ≥10 ng/mL) are summarized in [Table 2](#t2-gnl-10-818){ref-type="table"}. No associations were observed between the 25(OH)D level and age, sex, comorbidities (hypertension and DM), body mass index (BMI), or etiology of liver disease. Similarly, no significant associations were observed between the 25(OH)D level and the AST level, ALT level, creatinine level, or platelet count. However, the serum albumin level (p\<0.001), total bilirubin level (p=0.02), GGT level (p=0.044), and FIB-4 (p=0.048) were significantly associated with 25(OH)D deficiency. APRI and HOMA-IR were not associated with 25(OH)D \<10 ng/mL. As expected, 25(OH)D deficiency was strongly associated with LS (p\<0.001). Notably, seasonal timing of sampling for 25(OH)D measurement during spring to summer was linked to a higher 25(OH)D level than those during autumn and winter (p=0.019).

3. Univariate and multivariate analyses of factors associated with LS (≥9.5 kPa)
--------------------------------------------------------------------------------

Age, DM, AST level, GGT level, total bilirubin level, platelet count, albumin level, FIB-4, and APRI score were selected as significant factors associated with severe liver fibrosis ([Table 3](#t3-gnl-10-818){ref-type="table"}). In multivariate analysis, vitamin D deficiency was significantly associated with severe liver fibrosis (odds ratio \[OR\], 3.46; 95% confidence interval \[CI\], 1.47 to 8.14; p\<0.001) ([Table 3](#t3-gnl-10-818){ref-type="table"}) independent of other factors (age, DM, AST level, GGT level, total bilirubin level, albumin level, FIB-4, and APRI) and seasonal timing of sampling. In addition, there were significant associations between severe liver fibrosis and DM (OR, 3.04; 95% CI, 1.05 to 8.83; p=0.041) ([Table 3](#t3-gnl-10-818){ref-type="table"}) and the FIB-4 (OR, 2.01; 95% CI, 1.42 to 2.83; p\<0.001) ([Table 3](#t3-gnl-10-818){ref-type="table"}).

DISCUSSION
==========

In this study, we clarified the correlation between the vitamin D level and LS as measured by TE. Moreover, vitamin D deficiency was an independent factor associated advanced liver fibrosis as measured by TE in patients with compensated CLD. The vitamin D level and LS showed an inverse correlation (r=−0.190, p=0006) similar to that described previously in a German cohort (r=−0.267, p\<0.001).[@b16-gnl-10-818]

The LS value in the vitamin D deficiency group was significantly higher than those in the other two groups, but there was no difference in LS between the vitamin D insufficiency and sufficiency groups. DM, insulin resistance, and obesity are known to be associated with vitamin D deficiency.[@b28-gnl-10-818],[@b29-gnl-10-818] In the present study, we found that these conditions were commonly associated with NAFLD. Also, BMI, HOMA-IR, and prevalence of DM were not significantly different between patients with vitamin D levels of \<10 and ≥10 ng/mL. Therefore, it is likely that these results were largely attributable to the small proportion of patients with NAFLD (14%) in our cohort. Rode *et al*.[@b30-gnl-10-818] found that that the vitamin D level correlated with that of albumin. In our present study, the serum albumin level was also significantly associated with vitamin D deficiency. Of all patients, 17.5% had DM; this proportion is higher than that in the normal populations. In a Japanese study, the proportion of HCV patients with DM was 20.9% and that of HBV patients 11.9%.[@b31-gnl-10-818] The incidence of DM in patients with non-alcoholic fatty liver disease was 17.4%.[@b32-gnl-10-818] The higher proportion of DM patients (compared with that in the normal population) in the present study is explained by the fact that we included patients with diseases of various etiologies and those with compensated liver cirrhosis. Also, the work was performed in a tertiary hospital. This means that the proportion of patients with comorbidities such as DM was greater than that of patients visiting lower-tier clinics.

In this study, we used univariate and multivariate logistic regression analyses of the factors associated with advanced liver fibrosis on TE in patients with compensated CLD. After adjustment for the sampling timing, vitamin D deficiency was an independent factor associated with advanced liver fibrosis. Some studies have shown a correlation between vitamin D level and liver fibrosis.[@b14-gnl-10-818],[@b17-gnl-10-818],[@b33-gnl-10-818] These studies were based on liver biopsy. However, in addition to their small number, studies based on TE also lack cohorts with liver disease of various etiologies and Asian patients.[@b13-gnl-10-818],[@b16-gnl-10-818] This is the first study to assess the factors associated with advanced liver fibrosis by TE in various etiologies and Asian patients. Recent studies have suggested that DM is an independent factor for liver mortality and complications and leads to the progression of LS in patients with chronic HBV infection.[@b34-gnl-10-818],[@b35-gnl-10-818] Similar to previous studies, we found that DM was an independent factor of advanced liver fibrosis. FIB-4 and APRI were initially used in Western populations with viral HCV infection and exhibited good performance.[@b36-gnl-10-818] Consequently, these markers have been widely used for assessment of HBV-infected patients. We found that only FIB-4 was associated with advanced liver fibrosis. FIB-4 was reported previously to be more accurate for predicting liver fibrosis than APRI in patients with chronic HBV infection.[@b37-gnl-10-818] It is likely that these results could be largely attributed to chronic HBV infection, the main etiology in our cohort.

Since the first description of TE in 2003,[@b27-gnl-10-818] the clinical utility thereof has been evaluated in a number of studies.[@b9-gnl-10-818],[@b11-gnl-10-818],[@b38-gnl-10-818],[@b39-gnl-10-818] Most of these were cross-sectional studies assessing the diagnostic accuracy of TE in evaluation of liver fibrosis in various etiologies of CLD.[@b40-gnl-10-818] In a recent longitudinal study, TE was used to monitor disease progression.[@b41-gnl-10-818],[@b42-gnl-10-818] LS measurements by TE are difficult when the intercostal spaces are narrow, in obese patients, and in the presence of ascites. The most important environmental factors in vitamin D synthesis are sunlight exposure[@b43-gnl-10-818] and, to a much lower extent, diet and vitamin D dietary supplements. Information on the patients' dietary status was not collected in our study. However, the major source of vitamin D synthesis is derived from the skin through sunlight exposure. Seasonal timing of the sampling also had a significant influence on the vitamin D status in our study. Therefore, we adjusted vitamin D deficiency with the seasonal timing of the sampling. We excluded patients with decompensated CLD. LS values can be influenced by the degree of necroinflammation and the ALT level and can be limited in patients with ascites.[@b44-gnl-10-818] Patients with decompensated CLD have poorer nutritional support and more limited outdoor activity than those with compensated CLD, and both of these factors can affect vitamin D synthesis.

Few clinical studies have evaluated the beneficial effects and adverse toxicities of vitamin D supplementation on hepatic fibrosis. In their experimental model, Abramovich *et al*.[@b45-gnl-10-818] reported that vitamin D exposure inhibited proliferation of primary hepatic stellate cells and markedly suppressed the expression of collagen. Vitamin D administration also significantly prevented thioacetamide-induced liver fibrosis. Our study had some limitations. First, the cross-sectional nature of this study did not allow for determination of causal relationships between low serum 25(OH)D levels and liver fibrosis. Second, the degree of hepatic fibrosis could not be assessed through liver biopsy. However, we felt that TE could precisely indicate the degree of fibrosis because we could reduce the confounding effects of active inflammation on the LS value by TE examination after liver enzymes had reached a stable state. Third, other potential confounders that may affect serum vitamin D levels, such as the daily duration of exposure to sunlight and dietary status, were not evaluated for each patient.

However, there have been no clinical investigations of vitamin D supplementation in the treatment of human liver fibrosis. In conclusion, the serum 25(OH) D level and LS value obtained by TE in patients with compensated CLD exhibited an inverse linear correlation in this study. Although our study did not allow for determination of a causal relationship between vitamin D deficiency and liver fibrosis, vitamin D deficiency was independently associated with advanced liver fibrosis. Therefore, when clinicians encounter CLD patients with vitamin D deficiency, advanced liver fibrosis should be considered and a tailored follow-up performed. Further longitudinal prospective studies are needed to assess the relationship between vitamin D deficiency and liver fibrosis and to evaluate the effects of vitamin D administration.
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###### 

Patient's Characteristics

  Characteristic             No advanced fibrosis (n=132)   Advanced fibrosis (n=75)       Total (n=207)
  -------------------------- ------------------------------ ------------------------------ --------------------------------
  Age, yr                    46±11                          51±10                          48±11
  Male sex                   99 (75)                        52 (69.3)                      151 (72.9)
  Hypertension               17 (12.9)                      11 (14.7)                      28 (13.5)
  Diabetes mellitus          13 (9.8)                       23 (30.7)                      36 (17.4)
  Body mass index, kg/m^2^   24.15±3.5                      23.6±3.9                       23.9±3.6
  Etiology                                                                                 
   CHB\*                     83 (62.9)                      27 (36)                        110 (53.1)
   CHC^†^                    8 (6.1)                        7 (9.3)                        15 (7.3)
   NAFLD^‡^                  18 (13.6)                      7 (9.3)                        25 (12.1)
   Alcohol                   14 (10.6)                      27 (36)                        41 (19.8)
   Others                    9 (6.8)                        7 (9.3)                        16 (7.7)
  Sample season                                                                            
   Spring-summer             75 (56.8)                      38 (50.7)                      113 (54.6)
  AST, IU/L                  34.33±25.8                     56.16±42.43                    42.24±34.36
  ALT, IU/L                  40.16±38.53                    41.95±41.41                    40.81±39.5
  Serum creatinine, mg/dL    1.09±0.9                       0.92±0.18                      1.0±0.7
  Platelet count, ×10^9^/L   225.1±77.1                     178.7±89.2                     203.5±82.2
  Serum albumin, g/dL        4.38±0.4                       3.97±0.62                      4.2±0.5
  Total bilirubin, mg/dL     0.77±0.28                      1.45±1.62                      1.02±1.05
  GGT, IU/L                  61.9±78.5                      228.4±361.4                    122.9±240.2
  FIB4                       1.1 (0.7--1.6)                 2.6 (1.4--4.2)                 1.4 (0.9--2.7)
  APRI                       0.3 (0.2--0.5)                 0.7 (0.4--1.3)                 0.4 (0.2--0.8)
  HOMA-IR                    2.7 (1.8--3.8)                 3.9 (2.3--6.0)                 2.8 (1.8--4.4)
  Vitamin D status                                                                         
   25(OH)D deficiency        32 (24.2)                      40 (53.3)                      72 (34.8)
   25(OH)D insufficiency     70 (53.0)                      24 (32.0)                      94 (45.4)
   25(OH)D sufficiency       30 (22.8)                      11 (14.7)                      41 (19.8)
  Child-Pugh score           5 (123), 6 (7), 7 (2)          5 (50), 6 (11), 7 (9), 8 (5)   5 (173), 6 (18), 7 (11), 8 (5)

Data are presented as mean±SD, number (%), or median (interquartile range).

CHB, chronic hepatitis B virus; CHC, chronic hepatitis C; NAFLD, nonalcoholic fatty liver disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; FIB4, fibrosis 4 score; APRI, AST/platelet ratio index score; HOMA-IR, homeostasis model for assessment-insulin resistance.

###### 

Comparison of Patients according to Their Vitamin D Status (\<10 ng/mL vs ≥10 ng/mL)

                             25(OH)D              p-value             
  -------------------------- -------------------- ------------------- ---------
  Age, yr                    49.7±11.4            46.8±10.7           0.070
  Male sex                   53 (73.6)            98 (72.5)           0.875
  Hypertension               6 (8.3)              22 (16.2)           0.137
  Diabetes mellitus          17 (23.6)            19 (14)             0.085
  Body mass index, kg/m^2^   23.4±11.4            24.2±3.5            0.173
  Etiology                                                            0.184
   CHB                       34 (47.2)            76 (56.3)           
   CHC                       8 (11.1)             7 (5.2)             
   NAFLD                     6 (8.4)              19 (14.1)           
   Alcohol                   16 (22.2)            25 (18.5)           
   Others                    8 (11.1)             8 (5.9)             
  Sample season                                                       
   Spring-summer             31 (43)              82 (60.7)           0.019
  AST, IU/L                  47.4±39.3            39.5±31.2           0.116
  ALT, IU/L                  38.4±31.0            42.8±43.4           0.529
  Serum creatinine, mg/dL    0.95±0.17            1.07±0.93           0.298
  Platelet count, ×10^9^/L   200.9±99.2           210.6±75            0.457
  Serum albumin, g/dL        3.9±0.6              4.35±0.4            \<0.001
  Total bilirubin, mg/dL     1.31±1.6             0.86±0.5            0.020
  GGT, IU/L                  69 (27--148)         43 (24--89.5)       0.034
  Creatinine clearance       88.9±25.1            85.9±24.7           0.415
  Serum calcium              8.9±0.48             9.05±0.62           0.301
  Serum phosphate            3.4±0.84             3.4±0.74            0.888
  APRI                       0.48 (0.3--0.92)     0.36 (0.25--0.67)   0.069
  HOMA-IR                    3.11 (1.77--5.7)     2.81 (1.97--4.32)   0.464
  Liver stiffness, kPa       10.0 (5.85--23.45)   6.3 (4.7--9.7)      \<0.001
  Child-Pugh score           5.54±0.91            5.12±0.48           0.001

Data are presented as mean±SD, number (%), or median (interquartile range).

CHB, chronic hepatitis B; CHC, chronic hepatitis C; NAFLD, nonalcoholic fatty liver disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; APRI, AST/platelet ratio index score; HOMA-IR, homeostasis model for assessment-insulin resistance.

###### 

Factors Associated with Advanced Liver Fibrosis (TE ≥9.5 kPa)

  Variable                   Univariate   Multivariate                                 
  -------------------------- ------------ -------------- --------- ------ ------------ ---------
  Age, yr                    1.04         1.01--1.07     0.003                         
  Female sex                 1.32         0.70--2.49     0.378                         
  Body mass index            0.95         0.88--1.03     0.290                         
  Hypertension               1.16         0.51--2.63     0.718                         
  Diabetes mellitus          4.04         1.90--8.60     \<0.001   3.04   1.05--8.83   0.041
  Sample season                                                                        
   Autumn-winter             1.28         0.72--2.26     0.393                         
  25(OH)D, \<10 ng/mL        3.57         1.95--6.53     \<0.001   3.46   1.47--8.14   0.004
  AST, IU/L                  1.02         1.01--1.03     \<0.001                       
  ALT, IU/L                  1.01         0.99--1.01     0.754                         
  GGT, IU/L                  1.01         1.00--1.01     0.001     1.01   1.00--1.01   0.054
  Total bilirubin, mg/dL     3.99         1.91--8.35     \<0.001   2.75   0.86--8.81   0.089
  Platelet count, ×10^9^/L   0.99         0.99--1.00     0.001                         
  Albumin, g/dL              0.17         0.09--0.33     \<0.001                       
  HOMA-IR                    1.06         0.99--1.13     0.112                         
  FIB4                       1.96         1.49--2.58     \<0.001   2.01   1.42--2.83   \<0.001
  APRI                       4.53         2.28--8.96     \<0.001                       
  Child-Pugh score           3.78         2.05--6.96     \<0.001                       
  Creatinine clearance       0.99         0.98--1.01     0.859                         

OR, odds ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; HOMA-IR, homeostasis model for assessment-insulin resistance; FIB4, fibrosis 4 score; APRI, AST/platelet ratio index score.
